Epigenetische Wirkstoffentwicklung: Molekül Identifizierung und Optimierung, sowie Target Validierung (Z02)

具有潜在临床应用价值的高亲和力抑制剂的开发涉及鉴定抑制化合物的靶蛋白和先导结构的结构化过程。然后在化学修饰、结构分析和功能测定的迭代中优化这些先导物。Z02核心设施为CRC提供专业知识和设备，以扩大蛋白质生产，识别和验证合适的靶蛋白，获得三维结构，寻找候选化合物并优化配体筛选和蛋白质结晶的线索。

The development of high-affinity inhibitors with potential application in clinical therapy involves a structured process of identifying target proteins and lead structures for inhibitory compounds. Such leads are then optimised in iterative rounds of chemical modification, structural analysis and functional assays. The Z02 core facility provides the CRC with the know-how and equipment to scale-up protein production, identify and validate suitable target proteins, obtain three-dimensional structures, find candidate compounds and optimise leads for ligand screening and protein crystallisation.